Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ABDULLAH MUBARAK

Allopathic & Osteopathic Physicians Internal Medicine Transplant Hepatology

NPI
1336109925
CMS profile
60411
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$110,464.00

173 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ABDULLAH MUBARAK

NPI 1336109925 · CMS profile ID 60411

Allopathic & Osteopathic Physicians / Internal Medicine / Transplant Hepatology

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336109925?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ABDULLAH MUBARAK, NPI 1336109925, CMS profile ID 60411. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336109925?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ABDULLAH MUBARAK, NPI 1336109925, CMS profile ID 60411. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336109925?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ABDULLAH MUBARAK, NPI 1336109925, CMS profile ID 60411, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1336109925?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

173 matching records · $110,464.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 173 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 173.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $55.1806/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234412996 CMS
Gilead Sciences, Inc. $54.5506/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234413202 CMS
Gilead Sciences, Inc. $54.5506/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234413204 CMS
Gilead Sciences, Inc. $583.9706/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234365341 CMS
Gilead Sciences, Inc. $367.4806/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234366886 CMS
Ipsen Biopharmaceuticals, Inc $18.8306/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208830155 CMS
Intercept Pharmaceuticals, Inc. $22.6406/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249867987 CMS
ABBVIE INC. $136.3306/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1203167485 CMS
ABBVIE INC. $79.6406/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203167490 CMS
ABBVIE INC. $20.2106/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203167480 CMS
Gilead Sciences, Inc. $11.8406/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234583412 CMS
Intercept Pharmaceuticals, Inc. $23.4405/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249867981 CMS
Madrigal Pharmaceuticals $11.3105/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291202 CMS
Gilead Sciences, Inc. $9.7305/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234587328 CMS
Madrigal Pharmaceuticals $26.4205/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291198 CMS
Madrigal Pharmaceuticals $3,878.0005/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248291200 CMS
Ipsen Biopharmaceuticals, Inc $19.5405/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208830153 CMS
Madrigal Pharmaceuticals $13.6105/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291196 CMS
Gilead Sciences, Inc. $28.2104/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234449863 CMS
Gilead Sciences, Inc. $4,930.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234353929 CMS
Madrigal Pharmaceuticals $45.5004/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291194 CMS
Intercept Pharmaceuticals, Inc. $26.3804/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249867983 CMS
Ipsen Biopharmaceuticals, Inc $19.3804/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208830151 CMS
Madrigal Pharmaceuticals $3,878.0004/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248291190 CMS
Madrigal Pharmaceuticals $121.8404/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291192 CMS
Gilead Sciences, Inc. $22.9004/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234495688 CMS
Gilead Sciences, Inc. $16.5104/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234561811 CMS
Gilead Sciences, Inc. $1,001.7204/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234363825 CMS
Gilead Sciences, Inc. $113.5404/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234395386 CMS
Madrigal Pharmaceuticals $25.2204/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291188 CMS
Ipsen Biopharmaceuticals, Inc $5,049.0004/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1208830157 CMS
Ipsen Biopharmaceuticals, Inc $141.4004/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208830161 CMS
ABBVIE INC. $31.1403/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203167474 CMS
Gilead Sciences, Inc. $9.9703/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234586696 CMS
Intercept Pharmaceuticals, Inc. $23.6003/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249867977 CMS
Gilead Sciences, Inc. $3,790.0003/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234354808 CMS
Intercept Pharmaceuticals, Inc. $18.5603/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249867985 CMS
Intra-Sana Laboratories $22.6403/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251423230 CMS
Madrigal Pharmaceuticals $14.7203/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291186 CMS
Madrigal Pharmaceuticals $103.0403/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291182 CMS
Madrigal Pharmaceuticals $2,820.0003/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248291184 CMS
Ipsen Biopharmaceuticals, Inc $26.8203/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208830149 CMS
ABBVIE INC. $5.6003/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203167469 CMS
Gilead Sciences, Inc. $23.0403/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234494042 CMS
Madrigal Pharmaceuticals $10.4603/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248291180 CMS
Gilead Sciences, Inc. $568.7803/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234365471 CMS
Gilead Sciences, Inc. $59.4003/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234411136 CMS
Gilead Sciences, Inc. $57.6003/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234412370 CMS
Intercept Pharmaceuticals, Inc. $25.1502/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249867979 CMS
Gilead Sciences, Inc. $19.3802/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234534749 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $43,591.30 93
PY2020 $15,924.75 49
PY2021 $25,075.75 63
PY2022 $21,555.11 67
PY2023 $30,324.74 82
PY2024 $114,991.43 164
PY2025 $110,464.00 173

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $499,675.12 73
PY2024 Principal investigator $801,443.64 348
PY2023 Recipient $291.00 1
PY2023 Principal investigator $603,227.21 158
PY2022 Recipient $436.00 1
PY2022 Principal investigator $322,506.88 101
PY2021 Recipient $2,445.86 3
PY2021 Principal investigator $405,971.38 33
PY2020 Recipient $914.24 1
PY2020 Principal investigator $428,530.81 40
PY2019 Recipient $33,946.45 3
PY2019 Principal investigator $803,275.60 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Pharma SAS $2,223.90 12/19/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184305121
Principal investigator 1 Bausch Health US, LLC $1,549.13 12/16/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842527
Principal investigator 1 Madrigal Pharmaceuticals $2,359.54 12/11/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253846
Principal investigator 1 Ipsen Pharma SAS $393.38 12/04/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) No dispute reported 06/30/2026 1184305123
Principal investigator 1 Madrigal Pharmaceuticals $6,764.28 12/04/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253380
Principal investigator 1 Ipsen Bioscience Inc. $90.00 12/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545913
Principal investigator 1 Madrigal Pharmaceuticals $2,359.54 11/25/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252895
Principal investigator 1 Gilead Sciences, Inc. $340.00 11/18/2025 Non-covered Recipient Entity
Liver Center of Texas, PLLC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207115
Principal investigator 1 Ipsen Pharma SAS $772.40 11/07/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) No dispute reported 06/30/2026 1184305119
Principal investigator 1 Madrigal Pharmaceuticals $2,045.20 11/07/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252427
Principal investigator 1 Ipsen Bioscience Inc. $90.00 11/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545911
Principal investigator 1 Gilead Sciences, Inc. $4,722.00 10/21/2025 Non-covered Recipient Entity
Liver Center of Texas, PLLC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207110
Principal investigator 1 Ipsen Pharma SAS $1,143.26 10/16/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) No dispute reported 06/30/2026 1184305117
Principal investigator 1 Madrigal Pharmaceuticals $4,090.40 10/16/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251528
Principal investigator 1 Madrigal Pharmaceuticals $6,943.83 10/09/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251426
Principal investigator 1 Madrigal Pharmaceuticals $2,045.20 10/03/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251039
Principal investigator 1 Madrigal Pharmaceuticals $13,350.83 10/03/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248251042
Principal investigator 1 Ipsen Bioscience Inc. $90.00 10/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545909
Principal investigator 1 Madrigal Pharmaceuticals $2,045.20 09/23/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250562
Principal investigator 1 Madrigal Pharmaceuticals $4,404.74 09/18/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250236
Principal investigator 1 Ipsen Pharma SAS $271.80 09/12/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184305115
Principal investigator 1 Bausch Health US, LLC $6,561.00 09/11/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842523
Principal investigator 1 Madrigal Pharmaceuticals $2,045.20 09/04/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249527
Principal investigator 1 Ipsen Bioscience Inc. $90.00 09/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545907
Principal investigator 1 Madrigal Pharmaceuticals $2,045.20 08/26/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249086
Principal investigator 1 Madrigal Pharmaceuticals $4,584.29 08/21/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248881
Principal investigator 1 Bausch Health US, LLC $7,107.76 08/14/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842516
Principal investigator 1 Madrigal Pharmaceuticals $2,359.54 08/07/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248127
Principal investigator 1 Ipsen Bioscience Inc. $90.00 08/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545905
Principal investigator 1 Gilead Sciences, Inc. $3,632.00 07/22/2025 Non-covered Recipient Entity
Liver Center of Texas, PLLC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207103
Principal investigator 1 Madrigal Pharmaceuticals $4,898.63 07/22/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247410
Principal investigator 1 Madrigal Pharmaceuticals $4,680.49 07/17/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247147
Principal investigator 1 Madrigal Pharmaceuticals $7,464.16 07/17/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248247151
Principal investigator 1 Bausch Health US, LLC $10,935.02 07/14/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842519
Principal investigator 1 Madrigal Pharmaceuticals $6,764.28 07/10/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246829
Principal investigator 1 Madrigal Pharmaceuticals $22,905.47 07/08/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246673
Principal investigator 1 Madrigal Pharmaceuticals $17,000.00 07/07/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246626
Principal investigator 1 Madrigal Pharmaceuticals $79,901.05 07/07/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246630
Principal investigator 1 Ipsen Bioscience Inc. $90.00 07/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545903
Principal investigator 1 Madrigal Pharmaceuticals $4,404.74 06/24/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245997
Principal investigator 1 Gilead Sciences, Inc. $34,000.00 06/17/2025 Non-covered Recipient Entity
Liver Center of Texas, PLLC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207085
Principal investigator 1 Gilead Sciences, Inc. $16,059.00 06/17/2025 Non-covered Recipient Entity
Liver Center of Texas, PLLC
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207095
Principal investigator 1 Madrigal Pharmaceuticals $4,719.08 06/12/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245251
Principal investigator 1 Bausch Health US, LLC $9,568.13 06/11/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842551
Principal investigator 1 Bausch Health US, LLC $6,014.26 06/05/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842555
Principal investigator 1 Ipsen Pharma SAS $1,188.30 06/05/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (ELFINITY) No dispute reported 06/30/2026 1184305113
Principal investigator 1 Madrigal Pharmaceuticals $2,320.95 06/05/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244845
Principal investigator 1 Madrigal Pharmaceuticals $7,880.97 06/05/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248244969
Principal investigator 1 Ipsen Pharma SAS $2,223.90 06/04/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184305111
Principal investigator 1 Ipsen Bioscience Inc. $90.00 06/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545901
Principal investigator 1 Madrigal Pharmaceuticals $6,764.28 05/28/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244535
Principal investigator 1 Madrigal Pharmaceuticals $15,579.93 05/15/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243508
Principal investigator 1 Bausch Health US, LLC $4,442.35 05/13/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842561
Principal investigator 1 Bausch Health US, LLC $9,932.64 05/07/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842565
Principal investigator 1 Madrigal Pharmaceuticals $5,694.30 05/05/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248243163
Principal investigator 1 Ipsen Bioscience Inc. $90.00 05/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545899
Principal investigator 1 Madrigal Pharmaceuticals $5,694.30 04/24/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248242615
Principal investigator 1 Ipsen Bioscience Inc. $167.40 04/15/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545897
Principal investigator 1 Madrigal Pharmaceuticals $8,495.14 04/08/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241730
Principal investigator 1 Bausch Health US, LLC $6,264.86 04/01/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842546
Principal investigator 1 Ipsen Bioscience Inc. $90.00 04/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545895
Principal investigator 1 Bausch Health US, LLC $23,176.15 03/11/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842542
Principal investigator 1 Ipsen Pharma SAS $271.80 03/07/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184305109
Principal investigator 1 Madrigal Pharmaceuticals $34,521.97 03/06/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240436
Principal investigator 1 Bausch Health US, LLC $14,595.21 03/05/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842537
Principal investigator 1 Ipsen Bioscience Inc. $90.00 03/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545893
Principal investigator 1 Madrigal Pharmaceuticals $16,741.10 02/06/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239262
Principal investigator 1 Ipsen Bioscience Inc. $90.00 02/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545891
Principal investigator 1 Ipsen Bioscience Inc. $5,260.95 01/29/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545889
Principal investigator 1 Bausch Health US, LLC $5,862.37 01/28/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842534
Principal investigator 1 Ipsen Pharma SAS $2,427.70 01/24/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1184305107
Principal investigator 1 Bausch Health US, LLC $3,614.62 01/07/2025 Non-covered Recipient Entity
LIVER CENTER OF TEXAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842530
Principal investigator 1 Ipsen Bioscience Inc. $90.00 01/01/2025 Non-covered Recipient Entity
Liver Center Of Texas, Pllc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545887